Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250071 | 0.79 | MAPT (0.40) | MAPTLMNAALDH1A1NLRP3 | |
| SCHEMBL25824365 | 0.76 | MAPT (0.34) | MAPTLMNA | |
| SCHEMBL3693610 | 0.76 | SRD5A1 (0.40) | MAPTLMNAALDH1A1POLB | |
| SCHEMBL3297780 | 0.76 | KDM4E (0.31) | MAPTALDH1A1TDP1 | |
| SCHEMBL8247890 | 0.75 | MAPT (0.37) | MAPTLMNAALDH1A1NLRP3 | |
| SCHEMBL25138953 | 0.73 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL9742957 | 0.72 | KDM4E (0.38) | ALDH1A1TSHRPOLB | |
| SCHEMBL21962269 | 0.72 | ACHE (0.35) | — | |
| SCHEMBL11455327 | 0.71 | MEN1 (0.40) | LMNAALDH1A1TSHRNLRP3 | |
| SCHEMBL20713668 | 0.71 | MAPT (0.47) | MAPTLMNAALDH1A1TSHRNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| EP-3445757-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RES INC (US) | 2020-11-25 | — | — | EP | disclosed |